Skip to Main Content

Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

HepZero:Heparin Free Dialysis With Evodial

This study has been completed.

Sponsor:

Collaborator:

Statistical Analysis : CIC CHU Brabois Nancy

Information provided by (Responsible Party):

Gambro Lundia AB

ClinicalTrials.gov Identifier:

NCT01318486

First received: March 11, 2011

Last updated: May 17, 2016

Last verified: May 2016

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	February 2013
Primary Completion Date:	February 2013 (Final data collection date for primary outcome measure)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Laville M, Dorval M, Fort Ros J, Fay R, Cridlig J, Nortier JL, Juillard L, Dębska-Ślizień A, Fernández Lorente L, Thibaudin D, Franssen C, Schulz M, Moureau F, Loughraieb N, Rossignol P. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int. 2014 Dec;86(6):1260-7. doi: 10.1038/ki.2014.225. Epub 2014 Jul 9.

Rossignol P, Dorval M, Fay R, Ros JF, Loughraieb N, Moureau F, Laville M. Rationale and design of the HepZero study: a prospective, multicenter, international, open, randomized, controlled clinical study with parallel groups comparing heparin-free dialysis with heparin-coated dialysis membrane (Evodial) versus standard care: study protocol for a randomized controlled trial. Trials. 2013 Jun 1;14:163. doi: 10.1186/1745-6215-14-163.